Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Market Cap to Ebitda for ATE Citagenix

<< Previous

Bullboard Posts

Next >>

Post by nozzpackon Aug 10, 2021 8:03pm

230 Views

Post# 33682812

Market Cap to Ebitda for ATE Citagenix

The 2021 multiple of EV to Ebitda for drug pharmaceuticals 14.5 times.

As Citagenix has no debt, Market cap= EV

Ebitda in 2020 was $3.0 million.

However, revenues in Q1 of 2020 was just $1.2 million due to Covid lockdowns.

The remaining three quarters were solidly $2.8 m in sales per quarter.

Adjusting those 3 quarters for a full year and annual sales would have been close to $11,5 million and Ebitda of about $3.6 m.

So, using $3.6 million times 14.5 which equals Approx $47 million market cap or about $0,90 per share.

Average the two peer based estimates and Citagenix is worth about $1.00 per share

https://www.statista.com/statistics/1030072/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-united-states/